NewAmsterdam Pharma Co NV (NAMS)
16.23
+0.40
(+2.53%)
USD |
NASDAQ |
Sep 27, 16:00
16.26
+0.04
(+0.22%)
After-Hours: 20:00
NewAmsterdam Pharma Cash from Investing (Quarterly): -0.209M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -0.209M |
March 31, 2024 | -0.385M |
Date | Value |
---|---|
June 30, 2023 | -0.005M |
March 31, 2023 | -0.007M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-0.385M
Minimum
Mar 2024
-0.005M
Maximum
Jun 2023
-0.1515M
Average
-0.108M
Median
Cash from Investing (Quarterly) Benchmarks
Koninklijke Philips NV | -- |
uniQure NV | 77.94M |
ProQR Therapeutics NV | -0.12M |
Merus NV | 3.232M |
argenx SE | -513.76M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -53.98M |
Cash from Financing (Quarterly) | 4.658M |
Free Cash Flow | -170.36M |
Free Cash Flow Per Share (Quarterly) | -0.5721 |
Free Cash Flow to Equity (Quarterly) | -54.19M |
Free Cash Flow to Firm (Quarterly) | -54.19M |
Free Cash Flow Yield | -12.11% |